Citadel Advisors
PRLD icon

Citadel Advisors’s Prelude Therapeutics PRLD Stock Holding History

Citadel Advisors’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23,900
Closed -$18.4K – 14533
2025
Q1 		$18.4K Buy
23,900
+17,500
+273% +$16.3K ﹤0.01% 13209
2024
Q4 		$8.16K Buy
6,400
+5,900
+1,180% +$7.83K ﹤0.01% 13694
2024
Q3 		$1.03K Buy
500
+100
+25% +$463 ﹤0.01% 13916
2024
Q2 		$1.52K Buy
400
+200
+100% +$814 ﹤0.01% 13805
2024
Q1 		$948 Sell
200
-500
-71% -$1.95K ﹤0.01% 14216
2023
Q4 		$2.99K Buy
700
+500
+250% +$1.52K ﹤0.01% 13638
2023
Q3 		$618 Sell
200
-300
-60% -$1.13K ﹤0.01% 14017
2023
Q2 		$2.25K Buy
+500
New +$2.99K ﹤0.01% 13806
2023
Q1 		– Sell
-100
Closed -$604 – 15317
2022
Q4 		$604 Sell
100
-145,100
-100% -$930K ﹤0.01% 14621
2022
Q3 		$960K Sell
145,200
-152,000
-51% -$1.02M ﹤0.01% 7080
2022
Q2 		$1.55M Buy
297,200
+125,800
+73% +$640K ﹤0.01% 6074
2022
Q1 		$1.18M Buy
+171,400
New +$1.57M ﹤0.01% 7324

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citadel Advisors's PRLD Position: Q1 2026 in Review

Citadel Advisors opened a new position in Prelude Therapeutics (PRLD) in Q1 2026: 124,378 shares worth $425K. The stake represents ﹤0.01% of the portfolio and ranks #9691 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in PRLD as recently as Q2 2025.

Citadel Advisors first reported a position in PRLD in Q3 2020 and has held it in 18 quarters since. The position peaked at $3.34M in Q3 2020. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Citadel Advisors held 124,378 shares of Prelude Therapeutics worth $425K as of Q1 2026.
  • Prelude Therapeutics was a new Citadel Advisors position in Q1 2026.
  • Prelude Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9691 holding.
  • Citadel Advisors first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 18 quarters since.
  • Citadel Advisors's Prelude Therapeutics position peaked at $3.34M in Q3 2020.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.